Publications
325 results found
Grube E, Zoccai GB, Sangiorgi G, et al., 2005, Assessing the safety and effectiveness of Taxus in 183 patients with chronic total occlusions: Insights from the TRUE study, 17th Annual Transcatheter Cardiovascular Therapeutics Symposium/4th Annual Transcatheter Cardiovascular Therapeutics Inflammation Summit, Publisher: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC, Pages: 37H-38H, ISSN: 0002-9149
Rajagopal R, Musto C, La Manna A, et al., 2005, Thrombectomy and distal protection devices., Minerva Cardioangiol, Vol: 53, Pages: 415-430, ISSN: 0026-4725
Visible distal embolization is a relatively rare complication during percutaneous coronary interventions but it may occur in 15-20% of angioplasties in saphenous vein grafts (SVG) and in thrombus containing lesions of native coronary arteries, especially in the setting of acute myocardial infarction (AMI). Mechanical thrombectomy devices and distal protection devices have been introduced to reduce the incidence of distal embolisation. Angiojet thrombectomy has shown positive outcomes in thrombus containing lesions when compared with intracoronary thrombolysis but a randomised trial failed to show benefit in the context of AMI. The X-Sizer, Excimer LASER and various simple aspiration thrombectomy catheters show promise in treatment of AMI with improvement shown in surrogate end-points such as resolution of ST-elevation but there have been no randomised trials large enough to demonstrate changes in hard clinical end-points. Distal protection devices have come to be routinely used during SVG treatment and, after the results of the SAFER and FIRE trials; they became a treatment recommendation in the recently issued European Society of Cardiology (ESC) guidelines. For AMI, these devices showed great promise in early single-centre studies which have been offset by the lack of clinical benefit in the multi-centre EMERALD trial. Proximal occlusion devices may further decrease the incidence of distal embolisation, especially in the treatment of totally occluded SVGs or native arteries, by reversing the blood flow and offering protection at a very early stage of the procedure before wire passage. Despite continuous technical improvement and a growing number of miniaturised thrombectomy devices and filters, because of the paucity of controlled large studies, it remains unclear whether these devices will remain limited to niche' applications or will become a regular companion to balloons and stents in mainstream angioplasty procedures.
Sangiorgi GM, Colombo A, Biondi-Zoccai GGL, et al., 2005, Safety and effectiveness of paclitaxel-eluting stent implantation in over 1000 very high-risk patients - Insights from the true study, 27th Congress of the European-Society-of-Cardiology, Publisher: OXFORD UNIV PRESS, Pages: 706-706, ISSN: 0195-668X
Vitrella G, Sansa M, Bongo AS, et al., 2005, Target-vessel revascularisation among patients who received oral rapamicyn or placebo after bare- metal stent implantation - Eighteen-months clinical follow-up of the rapamune study, 27th Congress of the European-Society-of-Cardiology, Publisher: OXFORD UNIV PRESS, Pages: 696-696, ISSN: 0195-668X
Sangiorgi G, Agostoni P, Grube E, et al., 2005, Different clinical impact of the Taxus paclitaxel-eluting stent in non-insulin-requiring vs. insulin-requiring diabetic patients. insights from the TRUE study, 27th Congress of the European-Society-of-Cardiology, Publisher: OXFORD UNIV PRESS, Pages: 116-116, ISSN: 0195-668X
Antoniucci D, Migliorini A, Sangiorgi G, et al., 2005, Percutaneous treatment of left main coronary artery disease with taxus paclitaxel-eluting stent. An analysis of the TRUE study, 27th Congress of the European-Society-of-Cardiology, Publisher: OXFORD UNIV PRESS, Pages: 407-408, ISSN: 0195-668X
Agostoni P, Sangiorgi G, Antoniucci D, et al., 2005, Is paclitaxel-eluting stent a valid choice for diabetic patients?, 27th Congress of the European-Society-of-Cardiology, Publisher: OXFORD UNIV PRESS, Pages: 116-116, ISSN: 0195-668X
Sangiorgi G, Agostoni P, Biondi-Zoccai G, et al., 2005, Low target lesion revascularisation after the taxus paclitaxel-eluting stent in small vessels - An analysis from the TRUE study, 27th Congress of the European-Society-of-Cardiology, Publisher: OXFORD UNIV PRESS, Pages: 703-703, ISSN: 0195-668X
Di Mario C, Lafont A, 2005, Training in interventional cardiology in Europe: how to move from chaos to rational common programmes?, EuroIntervention, Vol: 1, Pages: 135-137, ISSN: 1774-024X
Ostermayer SH, Reisman M, Kramer PH, et al., 2005, Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation - Results from the international multi-center feasibility trials, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol: 46, Pages: 9-14, ISSN: 0735-1097
- Author Web Link
- Cite
- Citations: 336
Di Mario C, Sutaria N, 2005, Coronary angiography in the angioplasty era: Projections with a meaning, HEART, Vol: 91, Pages: 968-976, ISSN: 1355-6037
- Author Web Link
- Cite
- Citations: 26
Webb CM, Collins P, Di Mario C, 2005, Normal coronary physiology assessed by intracoronary Doppler ultrasound, HERZ, Vol: 30, Pages: 8-16, ISSN: 0340-9937
- Author Web Link
- Cite
- Citations: 5
Di Mario C, Griffiths H, Goktekin O, et al., 2004, Drug-eluting bioabsorbable magnesium stent., J Interv Cardiol, Vol: 17, Pages: 391-395, ISSN: 0896-4327
Current stent technology is based on the use of permanent implants that remain life long in the vessel wall, far beyond the time required for the prosthesis to accomplish its main goals of sealing dissection and preventing wall recoil. With the possibility to implant long vessel segments using antiproliferative drugs to prevent restenosis, the practice of transforming the coronary vessels into stiff tubes with a full metal jacket covering all side branches and being unable to adjust to the long-term wall changes, including wall remodeling with lumen ectasia becomes a serious concern. In this article, we describe the first biodegradable stent based on a magnesium alloy that allows controlled corrosion with release to the vessel wall and the blood stream of a natural body component such as magnesium with beneficial antithrombotic, antiarrhythmic, and antiproliferative properties. We also discuss the animal experiments and the initial clinical applications in 20 patients with implants below the knee, with final results soon to be released, and the plans for the first coronary study. The results of these last two studies will indicate whether the absence of a permanent implant and the antiproliferative properties shown in animals are sufficient to prevent the restenotic process in humans or whether the prosthesis must be modified by adding the biodegradable coating with conventional antiproliferative drugs.
Griffiths H, Bakhai A, West D, et al., 2004, Feasibility and cost of treatment with drug eluting stents of surgical candidates with multi-vessel coronary disease, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, Vol: 26, Pages: 528-534, ISSN: 1010-7940
- Author Web Link
- Cite
- Citations: 15
Di Mario C, Griffiths H, 2004, Treating multivessel disease in the era of coated stents: conclusion, HEART, Vol: 90, Pages: 1003-1003, ISSN: 1355-6037
- Author Web Link
- Cite
- Citations: 1
Di Mario C, Bolognese L, Maillard L, et al., 2004, Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS in AMI), AMERICAN HEART JOURNAL, Vol: 148, Pages: 378-385, ISSN: 0002-8703
- Author Web Link
- Cite
- Citations: 30
Di Mario C, Mikhail G, 2004, Treating multivessel disease in the era of coated stents: introduction, HEART, Vol: 90, Pages: 989-989, ISSN: 1355-6037
Mikhail GW, Airoldi F, Tavano D, et al., 2004, The use of drug eluting stents in single and multivessel disease: results from a single centre experience, HEART, Vol: 90, Pages: 990-994, ISSN: 1355-6037
- Author Web Link
- Cite
- Citations: 6
Vitrella G, Sansa M, Bongo AS, et al., 2004, Does oral rapamycin reduce intimal hyperplasia after dare metal stent implantation? In-stent volume measurements after intravascular ultrasound and computer-assisted three-dimensional reconstruction, ESC Congress 2004, Publisher: W B SAUNDERS CO LTD, Pages: 241-241, ISSN: 0195-668X
Di Mario C, Grube E, Nisanci Y, et al., 2004, MOONLIGHT: a controlled registry of an iridium oxide-coated stent with angiographic follow-up, INTERNATIONAL JOURNAL OF CARDIOLOGY, Vol: 95, Pages: 329-331, ISSN: 0167-5273
- Author Web Link
- Cite
- Citations: 18
Di Mario C, Griffiths H, O'Rourke B, et al., 2004, The impact of Sirolimus Eluting stents in interventional cardiology, INTERNATIONAL JOURNAL OF CARDIOLOGY, Vol: 95, Pages: 117-121, ISSN: 0167-5273
- Author Web Link
- Cite
- Citations: 5
Griffiths H, Bakhai A, West D, et al., 2004, Stents without restenosis: Enough to replace bypass surgery?, 54th Annual Scientific Session of the American-College-of-Cardiology, Publisher: ELSEVIER SCIENCE INC, Pages: 98A-98A, ISSN: 0735-1097
Di Mario C, Mara S, Flavio A, et al., 2004, Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study., Int J Cardiovasc Intervent, Vol: 6, Pages: 128-133, ISSN: 1462-8848
DESIGN: Prospective randomized, multicentre study. RATIONALE: Recanalisation of the culprit lesion is the main goal of primary angioplasty for acute myocardial infarction. With the exception of cardiogenic shock, staged procedures are performed in the presence of multivessel disease. The study hypothesis is that with modern non-thrombogenic stents (heparin coated) complete revascularization with multivessel treatment can be safely achieved during the primary angioplasty procedure with a lower need of subsequent revascularization procedures and at a lower cost. ENDPOINTS: PRIMARY: 12-month incidence of repeat revascularization (any revascularization, infarct related artery as well as non-infarct-related artery). SECONDARY: (1) in hospital repeat revascularization, reinfarction and death; (2) total hospital cost (including a 12 months follow-up period). METHODS: 69 patients with ST elevation Acute Myocardial Infarction (AMI), <12 hours after symptoms onset, undergoing primary angioplasty, with documented multivessel disease and both culprit lesion and 1 to 3 other lesions suitable for stent implantation. Unbalanced randomization between culprit lesion treatment only (n = 17) and complete multivessel treatment (n = 52, with 71 additional lesions treated). RESULTS: The two groups were well balanced in terms of clinical characteristics, number of diseased vessels and angiographic characteristics of the culprit lesion. In the complete multivessel treatment group 2.36 +/- 0.64 lesions per patient were treated using 2.73 +/- 0.78 heparin coated stents (1.00 lesions and 1.29 +/- 0.61 stents in the culprit treatment group, both p < 0.001). The duration of the procedure increased from 53 +/- 21 min (culprit treatment group) to 69 +/- 32 min (p = 0.032) and the amount of contrast used from 242 +/- 102 ml (culprit treatment group) to 341 +/- 163 ml (multivessel complete treatment), p = 0.025. A similar low incidence of in-hospital major adverse cardiac events was observed
Griffiths H, Bakhai A, West D, et al., 2003, Stents without restenosis: Enough to replace bypass surgery?, 15th Annual Transcatheter Cardiovascular Therapeutics Symposium, Publisher: EXCERPTA MEDICA INC, Pages: 59L-59L, ISSN: 0002-9149
- Author Web Link
- Cite
- Citations: 1
Liistro F, Di Mario C, 2003, Carotid artery stenting, HEART, Vol: 89, Pages: 944-948, ISSN: 1355-6037
- Author Web Link
- Cite
- Citations: 7
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.